retatrutide when will it be available Availability & Timeline Retatrutide GLP-3 | Advanced Triple-Agonist

Safety Concerns The proliferation of compounded GLP-1s was accompanied by safety concerns, largely because compounded drugs were not reviewed by the FDA prior to distribution

Unlike GLP-1RAs, particularly dulaglutide (254), SGLT-2 inhibitors have not demonstrated cardiovascular benefits in primary prevention among individuals with multiple cardiovascular risk factors (261)

Safety considerations also warrant continued attention

Without insurance, the price can vary from $149-299 for the pill, and $199-499 per month for the pen, depending on the dose

2 Thus, there is a tremendous amount of research under way to further elucidate these mechanisms and, more important, to discover pharmacologically based strategies that correct these separate, but intertwined, physiologic derangements